{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:57:44Z","timestamp":1793228264088,"version":"4.5.0"},"reference-count":179,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Renal cell carcinoma (RCC) is a highly vascularized and immunogenic malignancy with a complex tumor microenvironment (TME) that shapes disease progression and therapeutic resistance. Despite advances in immune checkpoint inhibitors (ICIs) and targeted therapies, clinical responses remain\u00a0heterogeneous, underscoring the need for a deeper understanding of\u00a0RCC immunobiology. This review comprehensively examines the immunosuppressive TME of RCC, emphasizing the roles of cytotoxic and immunosuppressive immune cells, carcinoma-associated fibroblasts (CAFs), abnormal vasculature, and extracellular matrix (ECM) remodeling in fostering immune evasion. This review summarized emerging biomarkers\u2014including PD-L1 expression, tumor mutational burden (TMB), gene mutations, and immune-based subtypes\u2014that may predict ICI response. Furthermore, we evaluate current immunotherapeutic strategies, such as ICIs, combination therapies, and novel approaches targeting immunosuppressive cells and metabolic pathways. While combination therapies have improved outcomes, challenges like toxicity and resistance persist, necessitating biomarker-driven patient stratification and optimized treatment sequencing. Future directions should focus on deciphering TME heterogeneity and developing precision immunotherapy strategies to enhance clinical efficacy in RCC.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1643533","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:34:32Z","timestamp":1756791272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Hui","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G Ital Nefrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21411","article-title":"Treatment of renal cell carcinoma: Current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00251-021-01246-1","article-title":"Prognostic implication and immunotherapy response prediction of a costimulatory molecule signature in kidney renal clear cell carcinoma","volume":"74","author":"Lin","year":"2022","journal-title":"Immunogenetics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03898-x","article-title":"Enhanced anti-tumor effects of combined electric fields, cabozantinib, and radiation therapy in metastatic renal cell carcinoma","author":"Heo","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85399","article-title":"Excellent outcomes with stereotactic body radiotherapy in an elderly patient with locally progressive immunotherapy-resistant renal cell carcinoma","volume":"17","author":"Torrisi","year":"2025","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.74647","article-title":"Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma","volume":"18","author":"Xu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006667","article-title":"Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma","volume":"11","author":"Xu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2025.43876","article-title":"Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years","volume":"64","author":"Decruyenaere","year":"2025","journal-title":"Acta Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ccell.2021.10.001","article-title":"Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma","volume":"39","author":"Au","year":"2021","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.01.022","article-title":"Radical nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma","volume":"9","author":"Yanagisawa","year":"2023","journal-title":"Eur Urol Focus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011162","article-title":"MIAT promotes tumor-infiltrating CD8(+) T-cell exhaustion and Malignant progression of renal cell carcinoma via activating JAK3\/STAT3 pathway","volume":"13","author":"Zhang","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0274","article-title":"Tim-3 expression on tumor-infiltrating PD-1(+)CD8(+) T cells correlates with poor clinical outcome in renal cell carcinoma","volume":"77","author":"Granier","year":"2017","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072532","article-title":"Immunotherapy in renal cell carcinoma: the future is now","volume":"21","author":"Deleuze","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168871","article-title":"CD40 cross-linking induces migration of renal tumor cell through nuclear factor of activated T cells (NFAT) activation","volume":"22","author":"Pontrelli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"217259","DOI":"10.1016\/j.canlet.2024.217259","article-title":"Single-nucleus sequencing unveils heterogeneity in renal cell carcinomas microenvironment: Insights into pathogenic origins and treatment-responsive cellular subgroups","volume":"604","author":"Zhang","year":"2024","journal-title":"Cancer Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04329-y","article-title":"Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus","volume":"149","author":"Zapa\u0142a","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-024-02059-y","article-title":"PD1\/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives","volume":"23","author":"Zhu","year":"2024","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"116975","DOI":"10.1016\/j.taap.2024.116975","article-title":"SLC11A1 promotes kidney renal clear cell carcinoma (KIRC) progression by remodeling the tumor microenvironment","volume":"487","author":"Wu","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.06.013","article-title":"Novel therapeutic strategies for metastatic prostate cancer care","volume":"19","author":"Cimadamore","year":"2025","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0853","article-title":"PI3K\/Akt signaling pathway regulates CD155 expression involved in resistance to cancer immunotherapy","author":"Kawase","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01143-7","article-title":"Immunotherapy for renal cell carcinoma-what more is to come","volume":"20","author":"Yochum","year":"2025","journal-title":"Target Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032042","article-title":"The variations\u2019 in genes encoding TIM-3 and its ligand, galectin-9, influence on ccRCC risk and prognosis","volume":"24","author":"Andrzejczak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1186\/s12967-024-06018-5","article-title":"Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC","volume":"22","author":"Zhang","year":"2024","journal-title":"J Transl Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13293-023-00540-9","article-title":"Sex differences in renal cell carcinoma: a single-cell analysis reveals exhausted CD8(+) T-cells highly infiltrated in males","volume":"14","author":"Ning","year":"2023","journal-title":"Biol Sex Differ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41419-022-04501-9","article-title":"Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"114725","DOI":"10.1016\/j.intimp.2025.114725","article-title":"Dual cytokine-engineered macrophages rejuvenate the tumor microenvironment and enhance anti-PD-1 therapy in renal cell carcinoma","volume":"156","author":"Liu","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: from basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3847","article-title":"Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin","volume":"19","author":"Remark","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16354","article-title":"Negative regulation of tumor-infiltrating NK cell in clear cell renal cell carcinoma patients through the exosomal pathway","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303605","article-title":"NK cell exhaustion in the tumor microenvironment","volume":"14","author":"Jia","year":"2023","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-021-01492-7","article-title":"Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy","volume":"21","author":"Hosseini","year":"2022","journal-title":"Mol Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12964-022-00957-6","article-title":"Exosomal AP000439.2 from clear cell renal cell carcinoma induces M2 macrophage polarization to promote tumor progression through activation of STAT3","volume":"20","author":"Shen","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1062968","article-title":"Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-\u03b2 and miR23a transfer","volume":"5","author":"Berchem","year":"2016","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233163","article-title":"PET imaging of the natural killer cell activation receptor NKp30","volume":"61","author":"Shaffer","year":"2020","journal-title":"J Nucl Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s13046-018-0952-7","article-title":"Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity","volume":"37","author":"Trotta","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.01.007","article-title":"Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis","volume":"391","author":"Zhang","year":"2017","journal-title":"Cancer Lett"},{"key":"B40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4062\/biomolther.2020.048","article-title":"Thymoquinone suppresses migration of human renal carcinoma caki-1 cells through inhibition of the PGE(2)-mediated activation of the EP2 receptor pathway","volume":"29","author":"Park","year":"2021","journal-title":"Biomol Ther (Seoul)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13046-024-03025-8","article-title":"GPR65 sensing tumor-derived lactate induces HMGB1 release from TAM via the cAMP\/PKA\/CREB pathway to promote glioma progression","volume":"43","author":"Yan","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1089\/107999004323142196","article-title":"IFN-gamma activates cAMP\/PKA\/CREB signaling pathway in murine peritoneal macrophages","volume":"24","author":"Liu","year":"2004","journal-title":"J Interferon Cytokine Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12967-023-04198-0","article-title":"Dental pulp stem cell-derived exosomes revitalize salivary gland epithelial cell function in NOD mice via the GPER-mediated cAMP\/PKA\/CREB signaling pathway","volume":"21","author":"Hu","year":"2023","journal-title":"J Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065860","article-title":"Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway","volume":"8","author":"Zhao","year":"2013","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097946","article-title":"The tumor immune microenvironment in clear cell renal cell carcinoma","volume":"24","author":"Monjaras-Avila","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03350-y","article-title":"Transforming growth factors \u03b2 and their signaling pathway in renal cell carcinoma and peritumoral space-transcriptome analysis","volume":"26","author":"Kajdaniuk","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"110224","DOI":"10.1016\/j.isci.2024.110224","article-title":"CXCL3\/TGF-\u03b2-mediated crosstalk between CAFs and tumor cells augments RCC progression and sunitinib resistance","volume":"27","author":"Wang","year":"2024","journal-title":"iScience"},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/cas.14237","article-title":"Calcitriol inhibits migration and invasion of renal cell carcinoma cells by suppressing Smad2\/3-, STAT3- and \u03b2-catenin-mediated epithelial-mesenchymal transition","volume":"111","author":"Xu","year":"2020","journal-title":"Cancer Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1532491","article-title":"NK cells in renal cell carcinoma and its implications for CAR-NK therapy","volume":"13","author":"Li","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"115322","DOI":"10.1016\/j.intimp.2025.115322","article-title":"Regulatory T cells in renal cell carcinoma: tumor-promoting mechanisms and emerging therapeutic strategies","volume":"163","author":"Li","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02702-x","article-title":"Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients","volume":"130","author":"Santagata","year":"2024","journal-title":"Br J Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","article-title":"Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells","volume":"96","author":"Sasidharan Nair","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010183","article-title":"Spatial and single-cell transcriptomics reveal cellular heterogeneity and a novel cancer-promoting Treg cell subset in human clear-cell renal cell carcinoma","volume":"13","author":"Song","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1157861","article-title":"Tumor-associated M2 macrophages in the immune microenvironment influence the progression of renal clear cell carcinoma by regulating M2 macrophage-associated genes","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s13046-024-03164-y","article-title":"Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma","volume":"43","author":"Liu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1167\/iovs.62.3.37","article-title":"CSF1\/CSF1R-mediated crosstalk between choroidal vascular endothelial cells and macrophages promotes choroidal neovascularization","volume":"62","author":"Zhou","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"123564","DOI":"10.1016\/j.lfs.2025.123564","article-title":"LKB1 activated by NaB inhibits the IL-4\/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization","volume":"370","author":"Liang","year":"2025","journal-title":"Life Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-020-00991-2","article-title":"Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer","volume":"13","author":"Zhao","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0507","article-title":"\u03b22-microglobulin maintains glioblastoma stem cells and induces M2-like polarization of tumor-associated macrophages","volume":"82","author":"Li","year":"2022","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2021.12249","article-title":"M2\u2212like tumour\u2212associated macrophage\u2212secreted IGF promotes thyroid cancer stemness and metastasis by activating the PI3K\/AKT\/mTOR pathway","volume":"24","author":"Lv","year":"2021","journal-title":"Mol Med Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.7150\/jca.37285","article-title":"The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases","volume":"11","author":"Pan","year":"2020","journal-title":"J Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1921","article-title":"Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes","volume":"69","author":"Rodriguez","year":"2009","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"66","DOI":"10.14348\/molcells.2014.2282","article-title":"Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR \u03b6 chain expression on CD8(+) T cells in chronic hepatitis C patients","volume":"37","author":"Zeng","year":"2014","journal-title":"Mol Cells"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2534","article-title":"Carfilzomib inhibits the proliferation and apoptosis of multiple myeloma cells by inhibiting STAT1\/COX-2\/iNOS signaling pathway","volume":"11","author":"He","year":"2022","journal-title":"Transl Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.apsb.2019.12.006","article-title":"Solute carrier transporters: the metabolic gatekeepers of immune cells","volume":"10","author":"Song","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S147041","article-title":"Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma","volume":"10","author":"Zhang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.123.319522","article-title":"PAD4-induced NETosis via cathepsin G-mediated platelet-neutrophil interaction in chAdOx1 vaccine-induced thrombosis-brief report","volume":"43","author":"Carnevale","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41420-022-01219-7","article-title":"Cancer-associated fibroblasts promote the stemness and progression of renal cell carcinoma via exosomal miR-181d-5p","volume":"8","author":"Ding","year":"2022","journal-title":"Cell Death Discov"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352632","article-title":"Investigating the complex interplay between fibroblast activation protein \u03b1-positive cancer associated fibroblasts and the tumor microenvironment in the context of cancer immunotherapy","volume":"15","author":"Kraxner","year":"2024","journal-title":"Front Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2023.0420","article-title":"Cancer-associated fibroblasts promote lymphatic metastasis in cholangiocarcinoma via the PDGF-BB\/PDGFR-\u03b2 Mediated paracrine signaling network","volume":"15","author":"Yan","year":"2024","journal-title":"Aging Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"177994","DOI":"10.1016\/j.ejphar.2025.177994","article-title":"Bruceine D inhibits CAF-promoted angiogenesis of breast cancer via suppressing IL-6-mediated activation of the STAT3\/Notch1\/VEGFR2 axis","volume":"1003","author":"Ma","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13062-025-00667-2","article-title":"CAF-derived exosomal miR-196b-5p after androgen deprivation therapy promotes epithelial-mesenchymal transition in prostate cancer cells through HOXC8\/NF-\u03baB signaling pathway","volume":"20","author":"Song","year":"2025","journal-title":"Biol Direct"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12470","article-title":"An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis","volume":"43","author":"Li","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf157","article-title":"CAF-derived LRRC15 orchestrates macrophage polarization and limits PD-1 immunotherapy efficacy in glioblastoma","volume":"26","author":"Luo","year":"2025","journal-title":"Neuro Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jid.2020.06.034","article-title":"Cancer-associated fibroblasts in mycosis fungoides promote tumor cell migration and drug resistance through CXCL12\/CXCR4","volume":"141","author":"Aronovich","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00740-4","article-title":"CAF-induced physical constraints controlling T cell state and localization in solid tumours","volume":"24","author":"Arpinati","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12967-022-03656-5","article-title":"Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients","volume":"20","author":"Zhang","year":"2022","journal-title":"J Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.773063","article-title":"CD248(+) cancer-associated fibroblasts: A novel prognostic and therapeutic target for renal cell carcinoma","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s43018-022-00411-z","article-title":"Cancer-associated fibroblasts in the single-cell era","volume":"3","author":"Lavie","year":"2022","journal-title":"Nat Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: A review","volume":"332","author":"Rose","year":"2024","journal-title":"Jama"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2024.2421699","article-title":"Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1\/HIF2\u03b1","volume":"21","author":"Li","year":"2025","journal-title":"Autophagy"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206693","article-title":"Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status","volume":"74","author":"Tumkur Sitaram","year":"2021","journal-title":"J Clin Pathol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/glia.24361","article-title":"Vascular endothelial growth factor promotes transdifferentiation of astrocytes into neurons via activation of the MAPK\/Erk-Pax6 signal pathway","volume":"71","author":"Lei","year":"2023","journal-title":"Glia"},{"key":"B88","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13287-016-0377-1","article-title":"C-reactive protein can upregulate VEGF expression to promote ADSC-induced angiogenesis by activating HIF-1\u03b1 via CD64\/PI3k\/Akt and MAPK\/ERK signaling pathways","volume":"7","author":"Chen","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01887","article-title":"Accomplices of the hypoxic tumor microenvironment compromising antitumor immunity: adenosine, lactate, acidosis, vascular endothelial growth factor, potassium ions, and phosphatidylserine","volume":"8","author":"Vaupel","year":"2017","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1111\/odi.14694","article-title":"Microvascular density analysis and histological parameters of oral cancer progression","volume":"30","author":"Batistella","year":"2024","journal-title":"Oral Dis"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3088","article-title":"Biomarkers of angiogenesis and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma from the phase III METEOR trial","volume":"28","author":"Denize","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13560","article-title":"High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma","volume":"109","author":"Seeber","year":"2018","journal-title":"Cancer Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12943-025-02315-9","article-title":"Exploring molecular and cellular mechanisms of Pre-Metastatic niche in renal cell carcinoma","volume":"24","author":"Zhou","year":"2025","journal-title":"Mol Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"27","DOI":"10.26444\/aaem\/192555","article-title":"Extracellular matrix metalloproteinases in pathophysiology, diagnostics and treatment of renal cell carcinoma - current state of knowledge and future perspectives","volume":"32","author":"Wi\u015bniowski","year":"2025","journal-title":"Ann Agric Environ Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/tox.23999","article-title":"Corosolic acid inhibits metastatic response of human renal cell carcinoma cells by modulating ERK\/MMP2 signaling","volume":"39","author":"Wu","year":"2024","journal-title":"Environ Toxicol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"101921","DOI":"10.1016\/j.mcp.2023.101921","article-title":"Formin-related protein 1 facilitates proliferation and aggressive phenotype of clear cell renal cell carcinoma through MAPK\/MMP2 pathway","volume":"71","author":"Ma","year":"2023","journal-title":"Mol Cell Probes"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-020-09566-w","article-title":"Squalene deters drivers of RCC disease progression beyond VHL status","volume":"37","author":"Rajamani","year":"2021","journal-title":"Cell Biol Toxicol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201700167","article-title":"Cancer associated fibroblasts: the architects of stroma remodeling","volume":"18","author":"Santi","year":"2018","journal-title":"Proteomics"},{"key":"B99","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1186\/s12967-025-06793-9","article-title":"COL6A2 in clear cell renal cell carcinoma: a multifaceted driver of tumor progression, immune evasion, and drug sensitivity","volume":"23","author":"Yang","year":"2025","journal-title":"J Transl Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat Commun"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020249","article-title":"Spatial distribution of tumor cells in clear cell renal cell carcinoma is associated with metastasis and a matrisome gene expression signature","volume":"17","author":"Bhat","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2420005122","article-title":"Complement C3 of tumor-derived extracellular vesicles promotes metastasis of RCC via recruitment of immunosuppressive myeloid cells","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B103","doi-asserted-by":"publisher","first-page":"108493","DOI":"10.1016\/j.envint.2024.108493","article-title":"HIF-1\u03b1\/m(6)A\/NF-\u03baB\/CCL3 axis-mediated immunosurveillance participates in low level benzene-related erythrohematopoietic development toxicity","volume":"184","author":"Cong","year":"2024","journal-title":"Environ Int"},{"key":"B104","doi-asserted-by":"publisher","first-page":"100315","DOI":"10.1016\/j.jbo.2020.100315","article-title":"c-Met expression in renal cell carcinoma with bone metastases","volume":"25","author":"Silva Paiva","year":"2020","journal-title":"J Bone Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg3517","article-title":"Metabolic rewiring tunes dermal macrophages in staphylococcal skin infection","volume":"8","author":"Forde","year":"2023","journal-title":"Sci Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01327-7","article-title":"Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma","volume":"80","author":"Hirsch","year":"2020","journal-title":"Drugs"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0316-3","article-title":"The immunology of renal cell carcinoma","volume":"16","author":"D\u00edaz-Montero","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1440269","article-title":"Targeting amino acid-metabolizing enzymes for cancer immunotherapy","volume":"15","author":"Grobben","year":"2024","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02676-2","article-title":"Melatonin modulates L-arginine metabolism in tumor-associated macrophages by targeting arginase 1 in lymphoma","volume":"397","author":"Kumari","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41419-022-04863-0","article-title":"Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.7150\/thno.97276","article-title":"Hepatocyte-specific Smad4 deficiency inhibits hepatocarcinogenesis by promoting CXCL10\/CXCR3-dependent CD8(+)- T cell-mediated anti-tumor immunity","volume":"14","author":"Xin","year":"2024","journal-title":"Theranostics"},{"key":"B112","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2024.10.015","article-title":"ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion","volume":"37","author":"Zhu","year":"2025","journal-title":"Cell Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.7150\/thno.105947","article-title":"Histone lactylation-driven B7-H3 expression promotes tumor immune evasion","volume":"15","author":"Ma","year":"2025","journal-title":"Theranostics"},{"key":"B114","doi-asserted-by":"publisher","first-page":"111765","DOI":"10.1016\/j.intimp.2024.111765","article-title":"Lactate acid promotes PD-1(+) Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia","volume":"130","author":"Zhang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1573039","article-title":"Lactate-mediated metabolic reprogramming of tumor-associated macrophages: implications for tumor progression and therapeutic potential","volume":"16","author":"Jin","year":"2025","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-025-00340-8","article-title":"Regulation of CD4\u2009+\u2009T cell differentiation and function by glucose metabolism","volume":"26","author":"Liu","year":"2025","journal-title":"Genes Immun"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000512","article-title":"The tumor microenvironment in renal cell cancer","volume":"31","author":"Mier","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010777","article-title":"Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1\/2 non-randomized ARTISTRY-1 trial","volume":"13","author":"Calvo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf240","article-title":"Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell Carcinoma","volume":"4","author":"De Vries-Brilland","year":"2025","journal-title":"Oncologist"},{"key":"B120","doi-asserted-by":"publisher","first-page":"113106","DOI":"10.1016\/j.intimp.2024.113106","article-title":"Prognostic significance of immune evasion-related genes in clear cell renal cell carcinoma immunotherapy","volume":"142","author":"Huang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1025330","article-title":"Ensemble deep learning enhanced with self-attention for predicting immunotherapeutic responses to cancers","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12935-022-02816-3","article-title":"Clinical potential of PD-1\/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy","volume":"22","author":"Jahangir","year":"2022","journal-title":"Cancer Cell Int"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071692","article-title":"Targeting the PD-1\/PD-L1 pathway in renal cell carcinoma","volume":"20","author":"Kammerer-Jacquet","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.11.002","article-title":"Prognostic and predictive value of tumor-infiltrating leukocytes and of immune checkpoint molecules PD1 and PDL1 in clear cell renal cell carcinoma","volume":"13","author":"Stenzel","year":"2020","journal-title":"Transl Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13560","article-title":"Effector Th1 cells under PD-1 and CTLA-4 checkpoint blockade abrogate the upregulation of multiple inhibitory receptors and by-pass exhaustion","volume":"167","author":"Horzum","year":"2022","journal-title":"Immunology"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773168","article-title":"What happens to the immune microenvironment after PD-1 inhibitor therapy","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03007-1","article-title":"A secondary role for hypoxia and HIF1 in the regulation of (IFN\u03b3-induced) PD-L1 expression in melanoma","volume":"71","author":"van Duijn","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15173","article-title":"Impact of PD-L1 protein expression on renal cell carcinoma histo-differentiation","volume":"41","author":"Tziakou","year":"2021","journal-title":"Anticancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03076-2","article-title":"Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer","volume":"71","author":"Guo","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B131","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01206-4","article-title":"Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma","volume":"27","author":"Hu","year":"2021","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004389","article-title":"Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models","volume":"10","author":"Chen","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1631136","article-title":"Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy","volume":"16","author":"Lee","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","article-title":"Integrated proteogenomic characterization of clear cell renal cell carcinoma","volume":"179","author":"Clark","year":"2019","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.029","article-title":"Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von hippel-lindau gene mutation status","volume":"70","author":"Messai","year":"2016","journal-title":"Eur Urol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12426","article-title":"Polybromo-1 (PBRM1), a SWI\/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma","volume":"113","author":"da Costa","year":"2014","journal-title":"BJU Int"},{"key":"B141","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","article-title":"ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity","volume":"187","author":"Maxwell","year":"2024","journal-title":"Cell"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-3382","article-title":"PP2Ac deficiency enhances tumor immunogenicity by activating STING-type I interferon signaling in glioblastoma","volume":"83","author":"Mondal","year":"2023","journal-title":"Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009455","article-title":"In vivo CRISPR\/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice","volume":"7","author":"Li","year":"2023","journal-title":"Blood Adv"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.23736\/S1824-4785.20.03250-1","article-title":"The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors","volume":"64","author":"Benitez","year":"2020","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205440","article-title":"LRP6 is a potential biomarker of kidney clear cell carcinoma related to prognosis and immune infiltration","volume":"16","author":"Lu","year":"2024","journal-title":"Aging (Albany NY)"},{"key":"B147","doi-asserted-by":"publisher","first-page":"3606362","DOI":"10.1155\/2023\/3606362","article-title":"CEACAM1 is a prognostic biomarker and correlated with immune cell infiltration in clear cell renal cell carcinoma","volume":"2023","author":"Yang","year":"2023","journal-title":"Dis Markers"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002949","article-title":"CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma","volume":"9","author":"Kl\u00fcmper","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2023.47","article-title":"Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena","volume":"6","author":"Roy","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00449-7","article-title":"Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial","volume":"24","author":"Grimm","year":"2023","journal-title":"Lancet Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184545","article-title":"Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma","volume":"10","author":"Schoenfeld","year":"2024","journal-title":"JCI Insight"},{"key":"B152","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.annonc.2025.03.016","article-title":"Prospective randomized phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","volume":"36","author":"Bergmann","year":"2025","journal-title":"Ann Oncol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1038\/s41467-021-25865-0","article-title":"Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals Malignancy","volume":"12","author":"Takamatsu","year":"2021","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2290787","DOI":"10.1080\/2162402X.2023.2290787","article-title":"A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid Malignancies","volume":"13","author":"Lin","year":"2024","journal-title":"Oncoimmunology"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ccell.2024.08.007","article-title":"Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8(+) T cells","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B161","doi-asserted-by":"publisher","first-page":"Jco2018792648","DOI":"10.1200\/JCO.2018.79.2648","article-title":"The immunobiology of kidney cancer","volume":"29","author":"Drake","year":"2018","journal-title":"J Clin Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20363","article-title":"Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer","volume":"8","author":"Santagata","year":"2017","journal-title":"Oncotarget"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.59","article-title":"Metabolic reprogramming in clear cell renal cell carcinoma","volume":"13","author":"Wettersten","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.1158\/1078-0432.CCR-07-0942","article-title":"Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma","volume":"13","author":"Riesenberg","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1186\/s12885-023-10971-7","article-title":"A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679\/ECHO-302)","volume":"23","author":"Lara","year":"2024","journal-title":"BMC Cancer"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.03.027","article-title":"Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016","volume":"186","author":"Gien","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030601","article-title":"Novel approaches with HIF-2\u03b1 Targeted therapies in metastatic renal cell carcinoma","volume":"16","author":"Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2972","article-title":"Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adu1727","article-title":"Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma","volume":"11","author":"Mou","year":"2025","journal-title":"Sci Adv"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194607","article-title":"Determining front-line therapeutic strategy for metastatic clear cell renal cell carcinoma","volume":"14","author":"Zarrabi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2066","article-title":"A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies","volume":"20","author":"Nguyen Duc","year":"2021","journal-title":"Pharm Stat"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.019","article-title":"First and second-line treatments in metastatic renal cell carcinoma","volume":"87","author":"Barragan-Carrillo","year":"2025","journal-title":"Eur Urol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009160","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0802","article-title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy","volume":"19","author":"Motzer","year":"2023","journal-title":"Future Oncol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"102787","DOI":"10.1016\/j.ctrv.2024.102787","article-title":"The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"129","author":"Zhang","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-023-02406-x","article-title":"Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis","volume":"28","author":"Washino","year":"2023","journal-title":"Int J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1643533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:34:33Z","timestamp":1756791273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1643533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":179,"alternative-id":["10.3389\/fimmu.2025.1643533"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1643533","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"article-number":"1643533"}}